You searched for
Tag:
Care
Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce European Commission Authorization of PRX-102 (pegunigalsidase alfa) for the Treatment of Fabry Disease
05/05/2023
Chiesi Farmaceutici S.p.A. Completes Acquisition of Amryt Pharma Plc
12/04/2023
2022 for Chiesi: The Group’s international growth continues
05/04/2023
Chiesi Global Rare Diseases Announces FDA Approval of Lamzede® (velmanase alfa-tycv) for Alpha-Mannosidosis
22/02/2023
Chiesi appoints Giuseppe Accogli as new Group CEO
27/01/2023
Chiesi Group endorses the Manifesto Against Gender-Based Violence
28/11/2022
Chiesi Group and Aptar partner to bring to market Disease Management Platform for Patients with Asthma and COPD
18/10/2022
Chiesi is recertified as a B Corp and sets new tougher objectives for action by 2025
22/09/2022
Chiesi Group brings together experts to discuss care for respiratory patients and presents a new treatment option for COPD at ERS Congress
05/09/2022
First carbon minimal pMDI is on track with the goal to benefit patients and planet
27/07/2022
Chiesi tracks actions taken for a healthier, more sustainable future
14/07/2022
Chiesi acquires pioneering therapeutic monoclonal antibodies portfolio against EMAP II as potential treatment for PAH
02/05/2022
Chiesi Group continues to grow
31/03/2022
A new clinical framework redefines the diagnosis of COPD Exacerbations
16/12/2021
Chiesi Group focuses on biological drugs: an investment of 85 million euros for an international centre of excellence in Parma
14/12/2021